<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>13</Volume>
				<Issue>8</Issue>
				<PubDate PubStatus="epublish">
					<Year>2012</Year>
					<Month>08</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>MTHFR C677T Polymorphism and Pancreatic Cancer Risk:a Meta-analysis</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>3763</FirstPage>
			<LastPage>3766</LastPage>
			<ELocationID EIdType="pii">26753</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>1970</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		<Abstract>&lt;b&gt;Background:&lt;/b&gt; Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme in the metabolism of folate,and the role of the MTHFR C677T polymorphism in pancreatic carcinogenesis is still controversial. &lt;br/&gt;&lt;b&gt;Method&lt;/b&gt;: Aliterature search was performed using Pubmed and CNKI databases for published studies through May 2012.We performed a meta-analysis of all relevant case-control studies that examined the association between MTHFRC677T polymorphism and pancreatic cancer risk. &lt;br/&gt;&lt;b&gt;Results&lt;/b&gt;: Finally, 9 individual case-control studies with a totalof 1,299 pancreatic cancer cases and 2,473 controls were included into this meta-analysis. &lt;br/&gt;&lt;b&gt;Results&lt;/b&gt;: This metaanalysisshowed there was an obvious association between MTHFR C677T polymorphism and pancreatic cancerrisk in East Asians (for allele model, OR = 1.67, 95%CI 1.11-2.51; For homozygote model, OR = 2.77, 95%CI1.40-5.48; for recessive model, OR = 1.96, 95%CI 1.54-2.50; for dominant model, OR = 2.11, 95%CI 1.01-4.41).However, no significant association was found in Caucasians. &lt;br/&gt;&lt;b&gt;Conclusion&lt;/b&gt;: The MTHFR C677T polymorphismis associated with pancreatic cancer risk, and a race-specific effect may exist in this association. More studieswith a larger sample size are needed to further clarify this association.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">methylenetetrahydrofolate reductase</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Genetic polymorphism</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Pancreatic cancer</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Meta-analysis</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_26753_c173cee3e1fd7a2d978f45e34c934eec.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
